Lintuzumab Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
VOR | F | Vor Biopharma Inc. | -0.56 | |
NTBL | F | Notable Labs, Ltd. | 3.94 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
CNCR | C | Loncar Cancer Immunotherapy ETF | 1.32 | |
IWC | C | iShares Microcap ETF | 0.02 | |
IWN | B | iShares Russell 2000 Value ETF | 0.01 | |
UWM | C | ProShares Ultra Russell2000 | 0.0 | |
VTHR | C | Vanguard Russell 3000 ETF | 0.0 |
Compare ETFs
- Lintuzumab
Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells.
Trials for AML were abandoned in 2010 when a phase IIb trial failed to show increased survival.
As of 2010, Seattle Genetics was conducting Phase II trials of lintuzumab in conjunction with bortezomib (marketed as Velcade) as a treatment for those with myelodysplastic syndromes.
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Featured Articles